Impromedica - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 190,591 | 150,740 | 167,350 | 1,589,579 | 4,145,258 | 3,279,901 | 3,366,782 | 2,496,908 |
| Profit before tax | 30,262 | 10,050 | 1,771 | 408,970 | 722,935 | 502,940 | 649,971 | 397,479 |
| Net profit | 28,741 | 9,545 | 1,056 | 352,274 | 616,439 | 427,290 | 552,341 | 333,887 |
| Equity | 91,961 | 101,506 | 102,562 | 454,836 | 733,179 | 546,469 | 671,520 | 464,527 |
| Liabilities | 19,507 | 20,367 | 23,989 | 600,696 | 523,328 | 124,018 | 137,368 | 107,864 |
| Non-current assets | 26,403 | 20,468 | 13,825 | 57,278 | 49,732 | 36,707 | 59,346 | 45,878 |
| Current assets | 85,065 | 101,405 | 112,726 | 998,254 | 1,206,775 | 633,780 | 749,542 | 526,513 |
| Total assets | 111,468 | 121,873 | 126,551 | 1,055,532 | 1,256,507 | 670,487 | 808,888 | 572,391 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 317,918 | 638,759 | 625,418 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +53.6% | -20.9% | +11.0% | +849.9% | +160.8% | -20.9% | +2.6% | -25.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 25.8% | 7.8% | 0.8% | 33.4% | 49.1% | 63.7% | 68.3% | 58.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 31.3% | 9.4% | 1.0% | 77.5% | 84.1% | 78.2% | 82.3% | 71.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 15.1% | 6.3% | 0.6% | 22.2% | 14.9% | 13.0% | 16.4% | 13.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 15.9% | 6.7% | 1.1% | 25.7% | 17.4% | 15.3% | 19.3% | 15.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.2 | 0.2 | 0.2 | 1.3 | 0.7 | 0.2 | 0.2 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 95,296 | 75,370 | 83,675 | 794,790 | 1,381,753 | 1,093,300 | 1,122,261 | 832,303 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Impromedica - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2021-11-16 | 2021-11-17 | 0.53 |
| 2021-10-28 | 2021-11-14 | 0.53 |
Impromedica - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2024-12-18 | 2024-12-28 | 6.16 |
| 2024-12-17 | 2024-12-17 | 107.69 |
| 2024-12-01 | 2024-12-05 | 108.14 |
| 2024-11-28 | 2024-11-30 | 38.38 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Impromedica, UAB (code 302563192) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year 2025, the company generated revenue of €2.50M and net profit of €333.9K, with a profit margin of 13.4%. Revenue declined by 25.8% year on year and by 23.9% over two years, following the stronger results seen in 2023 and 2024. Net profit followed the same pattern, rising from €427.3K in 2023 to €552.3K in 2024 before easing to €333.9K in 2025. The balance sheet remained solid, with total assets of €572.4K, equity of €464.5K and liabilities of €107.9K. The equity ratio stood at 81.2%, while debt-to-equity was 0.23, indicating limited leverage. Asset turnover was 4.36x, suggesting efficient use of assets. Return on equity was 71.9% and return on assets 58.3%. Revenue per employee was €832.3K and profit per employee €111.3K, pointing to high productivity in 2025.